

PATENT ASSIGNMENT

Electronic Version v1.1
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	Patent Security Release Agreement

CONVEYING PARTY DATA

Name	Execution Date
Goldman Sachs Lending Partners LLC	03/08/2011

RECEIVING PARTY DATA

Name:	Biovail International Laboratories SRL
Street Address:	Welches
City:	Christ Church
State/Country:	BARBADOS
Postal Code:	17154

Name:	Biovail International Laboratories (Barbados) SRL
Street Address:	Welches
City:	Christ Church
State/Country:	BARBADOS
Postal Code:	17154

PROPERTY NUMBERS Total: 100

Property Type	Number
Patent Number:	4855326
Patent Number:	5288505
Patent Number:	5518730
Patent Number:	5286497
Patent Number:	6129926
Patent Number:	5622717
Patent Number:	5370881
Patent Number:	5501858
Patent Number:	5439689
Patent Number:	5427811

CH \$4000.00 4855326

501466345

**PATENT
 REEL: 025950 FRAME: 0073**

Patent Number:	5520859
Patent Number:	5445769
Patent Number:	5529791
Patent Number:	5683720
Patent Number:	5458823
Patent Number:	5470584
Patent Number:	5709876
Patent Number:	6083430
Patent Number:	5622719
Patent Number:	5851552
Patent Number:	5728400
Patent Number:	6110935
Patent Number:	5834033
Patent Number:	5851454
Patent Number:	6132797
Patent Number:	5869098
Patent Number:	5840334
Patent Number:	6117453
Patent Number:	6013280
Patent Number:	5891845
Patent Number:	6337082
Patent Number:	6312724
Patent Number:	6228395
Patent Number:	5935600
Patent Number:	5980941
Patent Number:	6116880
Patent Number:	6090830
Patent Number:	6048547
Patent Number:	6117452
Patent Number:	6048541
Patent Number:	6391338
Patent Number:	6171607
Patent Number:	6270804
Patent Number:	6165512
Patent Number:	6096341

Patent Number:	6033686
Patent Number:	6268628
Patent Number:	6224939
Patent Number:	6313115
Patent Number:	6893661
Patent Number:	6143327
Patent Number:	7108866
Patent Number:	6348469
Patent Number:	6383516
Patent Number:	6730677
Patent Number:	6676966
Patent Number:	6660296
Patent Number:	7815937
Patent Number:	7780987
Patent Number:	7537784
Patent Number:	7241805
Patent Number:	7569610
Patent Number:	7563823
Patent Number:	7553992
Patent Number:	7649019
Patent Number:	7569611
Patent Number:	7572935
Patent Number:	7645901
Patent Number:	7585897
Patent Number:	7662407
Patent Number:	7579380
Patent Number:	7671094
Patent Number:	7645802
Patent Number:	7884136
Application Number:	10556492
Application Number:	10597803
Application Number:	11759413
Application Number:	11762343
Application Number:	11768764
Application Number:	11928908

Application Number:	11995436
Application Number:	11997675
Application Number:	12169852
Application Number:	12186853
Application Number:	12328828
Application Number:	12360673
Application Number:	12451515
Application Number:	12536772
Application Number:	12540144
Application Number:	12555695
Application Number:	12555720
Application Number:	12555732
Application Number:	12620720
Application Number:	12657924
Application Number:	12672137
Application Number:	12730339
Application Number:	12740223
Application Number:	12740786
Application Number:	12855620
Application Number:	60543531

CORRESPONDENCE DATA

Fax Number: (917)777-4104
Correspondence will be sent via US Mail when the fax attempt is unsuccessful.
Phone: 212-735-3000
Email: robert.wise@skadden.com
Correspondent Name: Louis Artime
Address Line 1: 4 Times Square
Address Line 2: Skadden Arps Slate Meagher & Flom LLP
Address Line 4: New York, NEW YORK 10036

ATTORNEY DOCKET NUMBER: 053470/1

NAME OF SUBMITTER: Louis Artime

Total Attachments: 19
source=Binder25#page1.tif
source=Binder25#page2.tif
source=Binder25#page3.tif
source=Binder25#page4.tif
source=Binder25#page5.tif

source=Binder25#page6.tif
source=Binder25#page7.tif
source=Binder25#page8.tif
source=Binder25#page9.tif
source=Binder25#page10.tif
source=Binder25#page11.tif
source=Binder25#page12.tif
source=Binder25#page13.tif
source=Binder25#page14.tif
source=Binder25#page15.tif
source=Binder25#page16.tif
source=Binder25#page17.tif
source=Binder25#page18.tif
source=Binder25#page19.tif

PATENT SECURITY RELEASE AGREEMENT

PATENT SECURITY RELEASE AGREEMENT, dated March 8, 2011 ("Patent Security Release"), by GOLDMAN SACHS LENDING PARTNERS LLC, a Delaware limited liability company located at 200 West Street, New York, NY 10282, in its capacity as collateral agent for the Secured Parties (in such capacity, the "Assignor" and "Collateral Agent"), in favor of VALEANT PHARMACEUTICALS INTERNATIONAL, a Delaware corporation located at One Enterprise, Aliso Viejo, CA 92656, VALEANT PHARMACEUTICALS NORTH AMERICA, a Delaware corporation located at One Enterprise, Aliso Viejo, CA 92656, CORIA LABORATORIES, LTD., a Delaware corporation located at 3801 Hulen Street, Fort Worth, TX 76107, DOW PHARMACEUTICAL SCIENCES, INC., a Delaware corporation located at 1330 Redwood Way, Petaluma, CA 94954, and ATON PHARMA, INC., a Delaware corporation located at 3150 Brunswick Pike, Ste 130, Lawrenceville, NJ 08648 (collectively, the "Assignees").

WITNESSETH:

WHEREAS, the Assignees and Assignor are parties to a Pledge and Security Agreement, dated as of September 27, 2010 (the "Pledge and Security Agreement"), pursuant to which the Assignees executed and delivered that certain Patent Security Agreement, dated as of September 27, 2010 (the "Patent Security Agreement") in order to record the continuing lien and security interest of Assignor in the Patent Collateral (as defined in the Patent Security Agreement) in the United States Patent and Trademark Office (the "PTO");

WHEREAS, the Patent Security Agreement was recorded with the Patent Division of the PTO on October 4, 2010 at Reel 25084/Frame 0169;

WHEREAS, the Secured Obligations have been paid and performed in full and any and all other conditions for termination of the Patent Security Agreement have been satisfied; and

WHEREAS, Assignor now desires to release its continuing lien on and security interest in and to the Assignees' right, title and interest in and to the Patent Collateral.

NOW, THEREFORE, in consideration of the foregoing and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Assignor and Assignees hereby agree as follows:

SECTION 1. Defined Terms. Capitalized terms used herein but not otherwise defined herein that are defined in the Patent Security Agreement shall have the meanings given to them in the Patent Security Agreement.

SECTION 2. Release of Security Interest in Patent Collateral. Assignor hereby terminates and releases in its entirety its continuing lien on and security interest in all of the Patent Collateral including, without limitation, the registrations and applications listed on Schedule A attached hereto.


SECTION 3. Governing Law. THIS PATENT SECURITY RELEASE AGREEMENT AND THE RIGHTS AND OBLIGATIONS OF THE PARTIES HEREUNDER AND ALL CLAIMS AND CONTROVERSIES ARISING OUT OF THE SUBJECT MATTER HEREOF WHETHER SOUNDING IN CONTRACT LAW, TORT LAW OR OTHERWISE SHALL BE GOVERNED BY, AND SHALL BE CONSTRUED AND ENFORCED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF NEW YORK, WITHOUT REGARD TO CONFLICTS OF LAW PROVISIONS THAT WOULD RESULT IN THE APPLICATION OF ANY OTHER LAW (OTHER THAN MANDATORY PROVISIONS OF LAW RELATING TO THE LAW GOVERNING PERFECTION AND THE EFFECT OF PERFECTION OF THE SECURITY INTEREST.)

SECTION 4. Counterparts. This Patent Security Release Agreement may be executed in one or more counterparts and by different parties hereto in separate counterparts, each of which when so executed and delivered shall be deemed an original, but all such counterparts together shall constitute but one and the same instrument. Delivery of an executed counterpart to this Patent Security Release Agreement by facsimile transmission or other electronic transmission shall be effective as delivery of a manually signed counterpart of this Patent Security Release Agreement.

[REMAINDER OF THIS PAGE INTENTIONALLY LEFT BLANK]

IN WITNESS WHEREOF, Assignor has caused this PATENT SECURITY RELEASE AGREEMENT to be executed and delivered by its duly authorized officer as of the date first above written.

GOLDMAN SACHS LENDING PARTNERS LLC,
as Assignor

By: 
Name: Gabe Jacobson
Title: Authorized Signatory

[Valeant Patent Security Release]

PATENT
REEL: 025950 FRAME: 0080

**SCHEDULE A
to
PATENT SECURITY RELEASE AGREEMENT**

[See Attached]

[EXECUTION COPY]

Valeant and Certain Valeant Subsidiaries

MWE	Country	Application No.	Filing Date	Patent No.	Issue Date	Title	Status	Owner
081117-0861	US	60/997,166	9/30/2007			SILICONE GEL-BASED COMPOSITIONS FOR WOUND HEALING AND SCAR REDUCTION	Completed/Provisional Application Expired	Valeant Pharmaceuticals International
081117-0028	US	61/082,162	7/18/2008			MODIFIED RELEASE FORMULATION AND METHODS OF USE	Completed	Valeant Pharmaceuticals International
081117-0012	US	60/851,084	10/10/2006			N-[2-AMINO-4-(PHENYLMETHOXY)PHENYL] CARBAMIC ACID ESTERS AND RELATED COMPOUNDS AS POTASSIUM CHANNEL ACTIVATORS	Completed	Valeant Pharmaceuticals International
081117-0013	US	60/850,867	10/10/2006			N-[2-AMINO-4-(PHENYLMETHOXY)PHENYL] AMIDES AND RELATED COMPOUNDS AS POTASSIUM CHANNEL ACTIVATORS	Completed	Valeant Pharmaceuticals International
081117-0268	US	60/839,642	8/22/2006			DERIVATIVES OF 3-(N-AZACYCLOALKYL) ANILIDES AS POTASSIUM CHANNEL ACTIVATORS	Completed	Valeant Pharmaceuticals International
081117-0270	US	60/867,482	11/28/2006			1,4 DIAMINO BICYCLIC RETIGABINE ANALOGUES AS POTASSIUM CHANNEL ACTIVATORS	Completed	Valeant Pharmaceuticals International
081117-0271	US	60/934,396	6/13/2007			DERIVATIVES OF 4-(N-AZACYCLOALKYL) ANILIDES AS POTASSIUM CHANNEL MODULATORS	Completed	Valeant Pharmaceuticals International
081117-0272	US	60/964,526	8/13/2007			DERIVATIVES OF 5-AMINO-4,6-DISUBSTITUTED INDOLE AND 5-AMINO-4,6-DISUBSTITUTED INDOLINE AS POTASSIUM CHANNEL MODULATORS	Completed	Valeant Pharmaceuticals International

[NYCORP-3240561v3;A V002.09/25/10-0624 p1]

MWE	Country	Application No.	Filing Date	Patent No.	Issue Date	Title	Status	Owner
081117-0273	US	60/962,862	8/1/2007			NAPHTHYRIDINE DERIVATIVES AS POTASSIUM CHANNEL MODULATORS	Completed	Valeant Pharmaceuticals International
081117-0863	US	60/839,941	8/23/2006			DERIVATIVES OF 4-(N-AZACYCLOALKYL) ANILIDES AS POTASSIUM CHANNEL ACTIVATORS	Completed	Valeant Pharmaceuticals International
081117-0865	US	60/811,463	6/5/2006			SUBSTITUTED ARYLAMINO-1,2,3,4-TETROHYDRO NAPHTHALENES AND-2,3-DIHYDRO-IH-INDENES AS KCNQ ACTIVATORS	Completed	Valeant Pharmaceuticals International
081117-0866	US	60/838,808	8/18/2006			DERIVATIVES OF 1,3-DIAMINO BENZENE AS POTASSIUM CHANNEL ACTIVATORS	Completed	Valeant Pharmaceuticals International
081117-0019	US	61/075,307	6/24/2008			BENZYLOXY ANILIDE DERIVATIVES USEFUL AS POTASSIUM CHANNEL MODULATORS	Completed	Valeant Pharmaceuticals International
081117-0428	US	60/936,720	6/21/2007			3-HYDROXYISOTHIAZOLE-4-CARBOXAMIDINE DERIVATIVES AS CHK2 INHIBITORS	Completed	Valeant Pharmaceuticals International
081117-0564	US	60/833,886	7/28/2006			DERIVATIVES OF N-(ARYLAMINO)SULFONAMIDES AS INHIBITORS OF MEK	COMPLETED	Valeant Pharmaceuticals International
081117-0688	US	11/347,145	2/3/2006	7465742	12/16/2008	NOVEL HETEROCYCLIC COMPOUNDS HAVING ANTI-HBV ACTIVITY	Granted	Valeant Pharmaceuticals International
081117-0803	US	60/678,636	5/5/2005			PHOSPHORAMIDATE PRODRUGS OF 2-METHYL RIBONUCLEOTIDES	Completed	Valeant Pharmaceuticals International
081117-0810	US	60/701,819	7/21/2005			SINGLE-ENANTIOMER THIAZOLIDINONES, OXAZOLIDINONES AND PYRROLIDINONES FOR HBV	Completed	Valeant Pharmaceuticals International

MWE	Country	Application No.	Filing Date	Patent No.	Issue Date	Title	Status	Owner
081117-0814	US	60/706,602	8/8/2005			SINGLE-ENANTIOMER N-(4-BROMO-OR-3-TRIFLUOROMETHYL) PHENYL-THIAZOLIDINONES, OXAZOLIDINONES AND PYRROLIDINONES FOR HBV	Completed	Valeant Pharmaceuticals International
081117-0926	US	12/143,672	6/20/2008			3-HYDROXYISOTHIAZOLE-4-CARBOXAMIDINE DERIVATIVES AS CHK2 INHIBITORS	Published	Valeant Pharmaceuticals International
081413-0782	US	08/459,151	6/2/1995	6683046	1/27/2004	PURIFICATION AND CHARACTERIZATION OF CYTOTOXIC LYMPHOCYTE MATURATION FACTOR AND MONOCLONAL ANTIBODIES THEREO	Granted	Valeant Pharmaceuticals International
081413-0938	US	08/329,764	10/27/1994	5792752	8/11/1998	8-CHLORO CAMP AND RELATED CAMP COMPOUNDS AS ANTINEOPLASTIC AGENTS [ADENAZOLE]	Granted	Valeant Pharmaceuticals International
081413-0939	US	08/225,097	4/8/1994	5843916	12/1/1998	ADMINISTRATION OF CYCLIC AMP ANALOGUES, INDIVIDUALLY AND IN PAIRS, TO INHIBIT NEOPLASTIC CELL GROWTH	Granted	Valeant Pharmaceuticals International
081117-0097	US	09/595,364	6/16/2000	6479463	11/12/2002	PURINE L-NUCLEOSIDES, ANALOGS AND USES THEREOF	Granted	Assignment recorded in parent application No. 09/291,907 on May 3, 1999, Reel/Frame 009916/0500 conveys interest to subsequent applications
084829-0068	US	08/430,154	4/26/1995	5670547	9/23/1997	MOISTURIZING VEHICLE FOR TOPICAL APPLICATION OF VITAMIN A ACID	Granted	Coria Laboratories, Ltd

M/W	Country	Application No.	Filing Date	Patent No.	Issue Date	Title	Status	Owner
081117-0413	US	08/438,537	5/10/1995	5763419	6/9/1998	TREATMENT OF MALIGNANT TUMORS WITH 8-CHLOROADENOSINE 3',5' CYCLIC MONOPHOSPHATE	Granted	Government of the United States of America, Represented by the Secretary of Health and Human Services
081117-0412	US	09/308,723	6/29/1999	6211201	4/3/2001	MULTIVALENT SALTS OF PYRIDOSTIGMINE AND RELATED COMPOUNDS	Granted	ICN Pharmaceuticals, Inc., provisional application no. 60/031,186 assignment recorded at Reel/Frame: 8278/0300
081117-0433	US	07/109,720	8/19/1993	5599546	2/4/1997	MEDICINAL FACIAL MASK	Granted	ICN Pharmaceuticals, Inc.
081117-0089	US	09/569,183	5/11/2000	6525191	2/25/2003	CONFORMATIONALLY CONSTRAINED L-NUCLEOSIDES	Granted	Isis Pharmaceuticals, Inc.
081117-0650	US	08/815,595	3/12/1997	5866555	2/2/1999	NOVEL DIABETIC SUPPLEMENT BAR	Granted	Medical Foods, Inc. - only one inventor assigned patent to Medical Foods, Inc.; the other 3 inventors assigned it in 1997 to Beth Israel Deaconess Medical Center, Inc.
081117-0806	US	60/681,332	5/16/2005			3', 5'-CYCLIC NUCLEOTIDE ANALOGS FOR TREATMENT OF HCV INFECTION	Completed	Ribapharm, Inc.
081117-0363	US	07/686,210	4/16/1991	5236952	8/17/1993	[3,5-DISUBSTITUTED PYROCATECHOL] CATECHOL DERIVATIVES	Granted	Valeant Global Acquisition Company PTE, LTD

-4-

[NYCORP:3240561V3:AV002:09/25/10-06.24 P]

MWE	Country	Application No.	Filing Date	Patent No.	Issue Date	Title	Status	Owner
081117-0364	US	08/048,685	4/16/1993	5389653	2/14/1995	[3,5-DISUBSTITUTED PYROCATECHOLE] CATECHOL DERIVATIVES	Granted	Valeant Global Acquisition Company PTE, LTD
081117-0365	US	08/527,160	10/21/1994	5476875	12/19/1995	[3,5-DISUBSTITUTED PYROCATECHOLE] CATECHOL DERIVATIVES	Granted	Valeant Global Acquisition Company PTE, LTD
081117-0366	US	08/528,588	9/15/1995	5633371	5/27/1997	[3,5-DISUBSTITUTED PYROCATECHOLE] CATECHOL DERIVATIVES	Granted	Valeant Global Acquisition Company PTE, LTD
081117-0367	US	08/784,554	1/21/1997	5705703	1/6/1998	[3,5-DISUBSTITUTED PYROCATECHOLE] CATECHOL DERIVATIVES	Granted	Valeant Global Acquisition Company PTE, LTD
081117-0397	US	09/007,612	1/15/1998	5877353	3/2/1999	PROCESS FOR THE PREPARATION OF BENZOPHENONE DERIVATIVES	Granted	Valeant Global Acquisition Company PTE, LTD
081117-0947	US	12/242,681	9/30/2008			SILICONE GEL-BASED COMPOSITIONS FOR WOUND HEALING AND SCAR REDUCTION	Published	Valeant Pharmaceuticals International
084829-0021	US	12/505,409	7/17/2009			MODIFIED RELEASE FORMULATION AND METHODS OF USE	Published	Valeant Pharmaceuticals International
081117-0937	US	12/181,126	7/28/2008			NAPHTHYRIDINE DERIVATIVES AS POTASSIUM CHANNEL MODULATORS	Published	Valeant Pharmaceuticals International
081117-0943	US	12/189,709	8/11/2008	7786146	8/31/2010	DERIVATIVES OF 5-AMINO-4,6-DISUBSTITUTED INDOLE AND 5-AMINO-4,6-DISUBSTITUTED INDOLINE AS POTASSIUM CHANNEL MODULATORS	Allowed	Valeant Pharmaceuticals International
084829-0022	US	12/491,055	6/24/2009			BENZYLOXY ANILIDE DERIVATIVES USEFUL AS POTASSIUM CHANNEL	Published	Valeant Pharmaceuticals International

-5-

[[NYCORP:3240561v3;AV002:09/25/10-06:24 PJ]]

MWE	Country	Application No.	Filing Date	Patent No.	Issue Date	Title	Status	Owner
084829-0065	US	12/698,070	2/1/2010			MODULATORS DERIVATIVES OF 4-(N-AZACYCLOALKYL) ANILIDES AS POTASSIUM CHANNEL MODULATORS	Pending	Valeant Pharmaceuticals International (Reel/Frame: 024994/0912)
084829-0051	US	12/690,889	1/20/2010			MODIFIED RELEASE FORMULATION AND METHODS OF USE	Pending	Valeant Pharmaceuticals International (Reel/Frame: 024903/0084)
084829-0052	US	12/691,680	1/21/2010			MODIFIED RELEASE FORMULATION AND METHODS OF USE	Pending	Valeant Pharmaceuticals International (Reel/Frame: 024903/0086)
081117-0014	US	11/870,368	10/10/2007			N-[2-AMINO-4-(PHENYLMETHOXY)PHENYL] AMIDES AND RELATED COMPOUNDS AS POTASSIUM CHANNEL MODULATORS	Published	Valeant Pharmaceuticals International, Inc.
081117-0266	US	11/810,114	6/4/2007			SUBSTITUTED ARYLAMINO-1,2,3,4-TETRAHYDRO NAPHTHALENES AND-2,3-DIHYDRO-1H-INDENES AS POTASSIUM CHANNEL MODULATORS	Published	Valeant Pharmaceuticals International, Inc.
081117-0267	US	11/893,724	8/16/2007			DERIVATIVES OF 1,3-DIAMINO BENZENE AS POTASSIUM CHANNEL MODULATORS	Published	Valeant Pharmaceuticals International, Inc.
081117-0269	US	11/894,877	8/22/2007			DERIVATIVES OF 4-(N-AZACYCLOALKYL) ANILIDES AS POTASSIUM CHANNEL MODULATORS	Published	Valeant Pharmaceuticals International, Inc.

MWE	Country	Application No.	Filing Date	Patent No.	Issue Date	Title	Status	Owner
081117-0860	US	11/946,822	11/28/2007			1, 4 DIAMINO BICYCLIC RETIGABINE ANALOGUES AS POTASSIUM CHANNEL MODULATORS	Published	Valeant Pharmaceuticals International, Inc.
081117-0924	US	12/138,251	6/12/2008			DERIVATIVES OF 4-(N-AZACYCLOALKYL) ANILIDES AS POTASSIUM CHANNEL MODULATORS	Published	Valeant Pharmaceuticals International, Inc.
081117-0512	US	12/014,739	1/15/2008			DRUG DELIVERY SYSTEM FOR ADMINISTERING AN ADJUSTABLE PRESET DOSE	Published	Valeant Pharmaceuticals North America
081117-0599	US	10/367,626	2/14/2003	7329241	2/12/2008	DRUG DELIVERY SYSTEM FOR ADMINISTERING AN ADJUSTABLE PRESET DOSE	Granted	Valeant Pharmaceuticals North America
081117-0400	US	08/122,685	9/17/1993	5462740	10/31/1995	RECTALLY-ADMINISTERED, EPILEPTIC-SEIZURE-INHIBITING COMPOSITION	Granted	Valeant Pharmaceuticals North America
081117-0122	US	08/736,166	10/28/1996	5852053	12/22/1998	USE OF 2-AMINO-4-(4-FLUOROBENZYLAMINO)-1-ETHOXY-CARBONYLAMINO BENZENE FOR THE PROPHYLAXIS AND TREATMENT OF THE NEURODEGENERATIVE DISORDERS	Granted	Valeant Pharmaceuticals North America
081117-0246	US	08/937,420	9/25/1997	5849789	12/15/1998	USE OF 4-AMINO-4-(4-FLUOROBENZYLAMINO)-1-ETHOXY-CARBONYLAMINO BENZENE FOR THE PROPHYLAXIS AND TREATMENT OF REDUCED CEREBRAL BLOOD SUPPLY	Granted	Valeant Pharmaceuticals North America
081117-0121	US	09/406,135	9/27/1999	6117900	9/12/2000	USE OF RETIGABINE FOR THE TREATMENT OF NEUROPATHIC PAIN	Granted	Valeant Pharmaceuticals North America

MVE	Country	Application No.	Filing Date	Patent No.	Issue Date	Title	Status	Owner
081117-0126	US	10/727,655	12/5/2003	7799832	9/21/2010	COMBINATIONS OF RETIGABINE AND SODIUM CHANNEL INHIBITORS OR SODIUM CHANNEL-INFLUENCING ACTIVE COMPOUNDS FOR TREATING PAINS	Allowed - no record at USPTO of release from security agreement with Regiment Capital III, L.P. - amended at recorded date 8/6/2004 Reel/Frame 015656/0150.	Valeant Pharmaceuticals North America
081117-0249	US	08/002,458	1/8/1993	5,384,330	1/24/1995	NOVEL PHARMACEUTICALLY ACTIVE 1,2,4-TRIAMINO-BENZENE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM	Granted	Valeant Pharmaceuticals North America
081117-0124	US	09/004,926	1/9/1998	5914425	6/22/1999	AMINO-4-(4-FLUOROBENZYLAMINO)-1-ETHOXYCARBONYLAMINO BENZENE, AND PROCESSES FOR THEIR PREPARATION	Granted	Valeant Pharmaceuticals North America
081117-0125	US	09/181,671	10/29/1998	6538151	3/25/2003	NOVEL MODIFICATIONS OF 2-AMINO-4-(4-FLUOROBENZYLAMINO)-1-ETHOXYCARBONYLAMINO BENZENE, AND PROCESSES FOR THEIR PREPARATION	Granted	Valeant Pharmaceuticals North America

MWE	Country	Application No.	Filing Date	Patent No.	Issue Date	Title	Status	Owner
081117-0037	US	09/467,443	12/20/1999	6423695	7/23/2002	CYTOKINE RELATED TREATMENTS OF DISEASE	Granted	Valeant Pharmaceuticals North America
081117-0042	US	10/227,235	8/22/2002	7638496	12/29/2009	NUCLEOSIDE ANALOGS WITH CARBOXAMIDINE MODIFIED MONOCYCLIC BASE	Granted	Valeant Pharmaceuticals North America
081117-0772	US	09/594,410	6/16/2000	6495677	12/17/2002	NUCLEOSIDE COMPOUNDS AND USES THEREOF	Granted	Valeant Pharmaceuticals North America
081413-0839	US	10/095,665	3/11/2002	7056895	6/6/2006	TIRAZOLE NUCLEOSIDE ANALOGS AND METHODS FOR USING SAME	Granted	Valeant Pharmaceuticals North America
084829-0026	US	12/558,416	9/11/2009			NUCLEOSIDE ANALOGS WITH CARBOXAMIDINE-MODIFIED MONOCYCLIC BASE	Pending	Valeant Pharmaceuticals North America
081117-0113	US	10/542,235	1/23/2006		9/21/2010	SYNTHESIS AND USE OF 2'-SUBSTITUTED-N6-MODIFIED NUCLEOSIDES	Allowed	Valeant Pharmaceuticals North America
081117-0416	US	08/576,817	12/21/1995	5723589	3/3/1998	CARBOHYDRATE CONJUGATED BIO-ACTIVE COMPOUNDS	Granted	Valeant Research & Development
081117-0038	US	09/595,365	10/5/2000	6455508	9/24/2002	METHODS FOR TREATING DISEASES WITH TIRAZOLE AND PYRROLO-PYRIMIDINE RIBOFURANOSYL NUCLEOSIDES	Granted	Valeant Research & Development
081117-0071	US	10/318,476	12/12/2002	6815542	11/9/2004	NUCLEOSIDE COMPOUNDS AND USES THEREOF	Granted	Valeant Research & Development
081117-0095	US	08/551,947	11/2/1995	5969135	10/19/1999	OLIGONUCLEOTIDE ANALOGS WITH AN AMINO ACID OR MODIFIED AMINO ALCOHOL RESIDUE	Granted	Valeant Research & Development
081117-0101	US	09/331,204	8/20/1999	6994959	2/7/2006	G-RICH OLIGO APTAMERS AND METHODS OF MODULATING AN	Granted	Valeant Research & Development

-9-

[NYCORP:5240561v3;AV002:09/25/10-06:24 pl]

MVE	Country	Application No.	Filing Date	Patent No.	Issue Date	Title	Status	Owner
						IMMUNE RESPONSE		opment
081117-0103	US	10/426,507	4/29/2003	7247621	7/24/2007	ANTIVIRAL PHOSPHONATE COMPOUNDS AND METHODS THEREFOR	Granted	Valeant Research & Development
081117-0104	US	10/826,439	4/15/2004	7189724	3/13/2007	QUINOXALINE DERIVATIVES HAVING ANTIVIRAL ACTIVITY	Granted	Valeant Research & Development
081117-0111	US	10/530,627	10/23/2002	7217815	5/15/2007	2-BETA-MODIFIED-6-SUBSTITUTED ADENOSINE ANALOGS AND THEIR USE AS ANTIVIRAL AGENTS	Granted	Valeant Research & Development
081117-0415	US	08/514,542	8/14/1995	5990299	11/23/1999	CONTROL OF CD44 GENE EXPRESSION FOR THERAPEUTIC USE	Granted	Valeant Research & Development
081117-0555	US	10/455,149	6/4/2003	6989451	1/24/2006	HETEROCYCLIC COMPOUNDS AND USES THEREOF	Granted	Valeant Research & Development
081117-0399	US	07/603,990	10/26/1990	5169849	12/8/1992	NASAL PHARMACEUTICAL COMPOSITIONS	Granted - expires 10/26/2010	XCEL Pharmaceuticals, Inc.

Dow Pharmaceuticals Sciences, Inc.

Granted Patents

Patent	Name	Date Issued	Expiration
US 6387383	Topical low viscosity gel composition	5/14/2002	8/3/2020
US 6468989	Gel Compositions Containing Metronidazole	10/22/2002	7/13/2020
US 6881726	Aqueous compositions containing Metronidazole	4/19/2005	2/21/2022 (Term extended by 59 days)
US 6517847	Topical gel delivery system lotion version	2/11/2003	8/3/2022 (Continuation of No. 6387383)
US 6389922	Skin Cleanser Comprising a Steareth, Poloxamer, and a Glyceryl Monocroster	7/8/2003	3/8/2021
US 7252816	Topical Acne Vulgaris Medication with A Sunscreen	8/7/2007	3/29/2026
US 7326408	Topical Acne Vulgaris Medication with A Sunscreen	2/5/2008	3/29/2026 (Divisional application of No. 7252816)
US 7348317	Aqueous compositions containing Metronidazole	3-25-08	10-23-2022 (Term extended by 303 days)
US 7368122	Skin Cream	5-6-08	3-8-2022
US 7704959	Azithromycin for the treatment of nodular acne	4-27-10	1-10-2028 (Term extended by 400 days)

U.S. Applications

Patent	Title	Date Filed	Products related	PCT Applications
US app. 12/069,745	Method for Stabilizing Polypeptides Lacking Methionine	2-13-08	None	No.
US app. 11/408,105 - assigned to both Dow and Dermalogix Partners, Inc.	USE OF A CLOBETASOL SPRAY FORMULATION TO TREAT PSORIASIS.	4-20-06	Clobex	Yes.
US App. 11/490,896	Alpha Hydroxy Acid Sustained Release Formulation	7-21-06	Xerate Cream/Lotion	No.

No. 12/799,401	Azithromycin for the treatment of Nodular Acne - Continued	4-23-10,	Azithromycin	No.
US App. 11/654,921	Two-Phase Mucoadhesive Composition	1-18-07	Del-Lab	Yes. (No national)
US App. 11/699,906	Silicone Based Emulsions for Topical Application	1-30-07	None	Yes.
US Serial No. 12/002,417	Controlled Release Azithromycin Solid Dosage Forms	12-17-07	Azithromycin	Yes.
US App. 12/006,531	Compositions and Methods for Treating Diseases of the Nail	1-3-08	IDP-108	Yes.
Filed 7-8-10	Compositions and Methods for Treating Diseases of the Nail (Surface Tension)	7-8-10	IDP-108	Yes.
US Serial No. 12/012,413	Methods and Compositions for Increasing Solubility of Azole Drug Compounds that are Poorly Soluble in Water	2-2-08	IDP-115	Yes. (No national)
US Serial No. 12/072,578	Method for Increasing Solubility of Betacyclodextrin	2-27-08	Metrogel	No.
US Serial No. 12/231,586	Azithromycin for Treatment of Skin Disorders	9-4-08	Azithromycin	Yes.
US Serial No. 12/319,978	Iniquinod Formulation	1-14-09	IDP-109	Yes.
US serial no. 12/589,680	Aqueous compositions Containing Metronidazole	10-27-09	Metrogel	No.
US serial No. 12/455,525	Topical Pharmaceutical Formulations Containing a Low Concentration of Benzoyl Peroxide in Suspension in Water and a Water-Miscible Organic Solvent	6-3-09	Acaanya	Yes.
US Serial No. 12/589,236	METHOD FOR OBTAINING A STABLE DISPERSION OF BENZOYL PEROXIDE	10-20-09	IDP-110/111	Yes.

Dow - National Phase Applications

I. Gel Compositions Containing Metronidazole (HPBCD) - assigned to Dow Pharmaceutical Sciences

Title	Country Name	Application No.	Status	Owner
Gel Compositions Containing Metronidazole (HPBCD)	U.S.	09/615,169	6468989 10-22-2002	Dow Pharmaceu- tical Sci- ences, Inc.
Aqueous Compositions Containing Metronidazole (Metro BCD)	U.S.	10/033,835	6881726 4-19-05	Dow Pharmaceu- tical Sci- ences, Inc.
Topical Low-Viscosity Gel Composition	U.S.	09/632,508	6387383 5-14-2002	Dow Pharmaceu- tical Sci- ences, Inc.
Topical Low-Viscosity Gel Composition	U.S.	10/096,516	6517847 2-11-2003	Dow Pharmaceu- tical Sci- ences, Inc.
Use of a Clobetazol Spray Formulation to Treat Psoriasis	U.S.	No.11/408,105 dated 4- 20-06		Dow Pharmaceu- tical Sci- ences, Inc.
Use of a Clobetazol Spray Formulation to Treat Psoriasis	US	PCT No. 2006/115987		Dow Pharmaceu- tical Sci- ences, Inc.
Azithromycin for Nodular Acne	US	No. 60/849,065 date: 10-3-06		Dow Pharmaceu- tical Sci- ences, Inc.
Azithromycin for Nodular Acne	US	No. PCT/US2007/020583		Dow Pharmaceu- tical Sci- ences, Inc.
Azithromycin for Treatment of Skin Disorders (Low Dose)	US	60/967,504		Dow Pharmaceu- tical Sci- ences, Inc.
Azithromycin for Treatment of Skin Disorders (Low Dose)	US	PCT/US2008/010355		Dow Pharmaceu- tical Sci- ences, Inc.

Title	Country Name	Application No. US Serial No.	Status	Owner
Controlled Release Azithromycin Solid Dosage Forms	US	12/002,417		Dow Pharmaceutical Sciences, Inc.
Controlled Release Azithromycin Solid Dosage Forms	US	PCT/US2008/009169		Dow Pharmaceutical Sciences, Inc.
Compositions and Methods for Treating Diseases of the Nail	US	US App. 12/006,531		Dow Pharmaceutical Sciences, Inc.
Compositions and Methods for Treating Diseases of the Nail	US	PCT/US2008/014107		Dow Pharmaceutical Sciences, Inc.
Imiquimod Formulation	US	12/319,978		Dow Pharmaceutical Sciences, Inc.
Imiquimod Formulation	US	PCT/US2009/000218		Dow Pharmaceutical Sciences, Inc.

Afon Pharma, Inc.

Docket Number	Title	Country	Subtype	Status	Application Number	Application Date	Patent Number	Grant Date	Expiration Date
089922-0101	USES OF TRENTINE AND PENICILLAMINE AS COUNTERMEASURES TO METAL CONTAMINATION	US	Regular	Pending	12/180130	7/25/2008			7/25/2028
089922-0200	OCULAR DRUG DELIVERY DEVICES	US	Provisional	Pending	61/256915	10/30/2009			10/30/2010
089922-0300	STEREOSELECTIVE SYNTHESIS OF METYROSINE	US	Provisional	Pending	61/256926	10/30/2009			10/30/2010